140 related articles for article (PubMed ID: 20083870)
1. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events.
Thomson VS; John B; George P; Joseph G; Jose J
J Postgrad Med; 2009; 55(4):252-6. PubMed ID: 20083870
[TBL] [Abstract][Full Text] [Related]
2. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
[TBL] [Abstract][Full Text] [Related]
3. Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease.
Liu T; Zhang J; Chen X; Feng X; Fu SW; McCaffrey TA; Liu M
Gene; 2015 Oct; 571(1):23-7. PubMed ID: 26095809
[TBL] [Abstract][Full Text] [Related]
4. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction.
Bruno A; McConnell JP; Cohen SN; Tietjen GE; Wallis RA; Gorelick PB; Bang NU
Stroke; 2004 Mar; 35(3):727-30. PubMed ID: 14963281
[TBL] [Abstract][Full Text] [Related]
5. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Eikelboom JW; Hirsh J; Weitz JI; Johnston M; Yi Q; Yusuf S
Circulation; 2002 Apr; 105(14):1650-5. PubMed ID: 11940542
[TBL] [Abstract][Full Text] [Related]
6. Aspirin dosage and thromboxane synthesis in patients with vascular disease.
Hart RG; Leonard AD; Talbert RL; Pearce LA; Cornell E; Bovill E; Feinberg WM
Pharmacotherapy; 2003 May; 23(5):579-84. PubMed ID: 12741431
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of urinary 11-dehydro-thromboxane B
Vasudevan A; Tecson KM; Bennett-Firmin J; Bottiglieri T; Lopez LR; Peterson M; Sathyamoorthy M; Schiffmann R; Schussler JM; Swift C; Velasco CE; McCullough PA
Catheter Cardiovasc Interv; 2018 Oct; 92(4):653-658. PubMed ID: 29193683
[TBL] [Abstract][Full Text] [Related]
8. Comparison of aspirin response measured by urinary 11-dehydrothromboxane B2 and VerifyNow aspirin assay in patients with ischemic stroke.
Dharmasaroja PA; Sae-Lim S
J Stroke Cerebrovasc Dis; 2014; 23(5):953-7. PubMed ID: 24126290
[TBL] [Abstract][Full Text] [Related]
9. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease.
Addad F; Chakroun T; Abderazek F; Ben-Farhat M; Hamdi S; Dridi Z; Gamra H; Hassine M; Samama MM; Elalamy I
J Thromb Thrombolysis; 2010 Jan; 29(1):108-13. PubMed ID: 19381450
[TBL] [Abstract][Full Text] [Related]
10. [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease].
Liu TF; Zhang JW; Chen XH; Feng XR; Bai ZS; Liu ML
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 47(6):920-4. PubMed ID: 26679651
[TBL] [Abstract][Full Text] [Related]
11. Aspirin resistance in off-pump coronary artery bypass grafting.
Wang Z; Gao F; Men J; Ren J; Modi P; Wei M
Eur J Cardiothorac Surg; 2012 Jan; 41(1):108-12. PubMed ID: 21636287
[TBL] [Abstract][Full Text] [Related]
12. Screening for aspirin resistance in stable coronary artery patients by three different tests.
Chakroun T; Addad F; Abderazek F; Ben-Farhat M; Hamdi S; Gamra H; Hassine M; Ben-Hamda K; Samama MM; Elalamy I
Thromb Res; 2007; 121(3):413-8. PubMed ID: 17553552
[TBL] [Abstract][Full Text] [Related]
13. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects.
Floyd CN; Goodman T; Becker S; Chen N; Mustafa A; Schofield E; Campbell J; Ward M; Sharma P; Ferro A
Br J Clin Pharmacol; 2014 Aug; 78(2):320-8. PubMed ID: 25099258
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
15. Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28780510
[TBL] [Abstract][Full Text] [Related]
16. Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients.
Bruno A; McConnell JP; Mansbach HH; Cohen SN; Tietjen GE; Bang NU
Stroke; 2002 Jan; 33(1):57-60. PubMed ID: 11779889
[TBL] [Abstract][Full Text] [Related]
17. Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers.
Dharmasaroja PA; Sae-Lim S
Blood Coagul Fibrinolysis; 2010 Oct; 21(7):649-52. PubMed ID: 20689403
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet effect of aspirin in patients with coronary artery disease.
Grove EL
Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
[TBL] [Abstract][Full Text] [Related]
19. Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin.
Bliden KP; Singla A; Gesheff MG; Toth PP; Tabrizchi A; Ens G; Guyer K; Singh M; Franzese CJ; Stapleton D; Tantry US; Gurbel PA
Thromb Haemost; 2014 Aug; 112(2):323-31. PubMed ID: 24763965
[TBL] [Abstract][Full Text] [Related]
20. Differential Impact of Serial Measurement of Nonplatelet Thromboxane Generation on Long-Term Outcome After Cardiac Surgery.
Kakouros N; Gluckman TJ; Conte JV; Kickler TS; Laws K; Barton BA; Rade JJ
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29097390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
